Europe - EBR:FAGR - BE0003874915 - Common Stock
The current stock price of FAGR.BR is 20.3 EUR. In the past month the price decreased by -2.86%. In the past year, price increased by 9.56%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| AMP.MI | AMPLIFON SPA | 24.81 | 2.98B | ||
| UPR.I | UNIPHAR PLC | 17.09 | 975.98M | ||
| ILM1.DE | MEDIOS AG | 18.73 | 353.57M | ||
| BLC.PA | BASTIDE LE CONFORT MEDICAL | 375.71 | 193.83M | ||
| PRE.MI | PREDICT SPA | 13.67 | 4.57M | ||
| VMED.DE | VIROMED MEDICAL AG | N/A | 74.52M |
Fagron NV engages in the development, marketing, and distribution of healthcare products and services. The company is headquartered in Nazareth, Oost-Vlaanderen and currently employs 3,989 full-time employees. The company went IPO on 2007-10-05. The firm specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The company operates through the following segments: Essentials, enable pharmacists to compound safe products and optimize their compounding process with equipment and packaging. The portfolio includes pharmaceutical raw materials, compounding equipment, packaging, and supplies; Brands, focuses on developing semi-finished products and pharmaceutical-grade vehicles and reduce the workload for pharmacists; Compounding Services, utilizes raw materials from the Essentials segment and vehicles from the Brands segment for compounding activities, offering both sterile and non-sterile compounded products tailored to patients' specific needs.
FAGRON
Venecoweg 20A
Nazareth OOST-VLAANDEREN BE
Employees: 3989
Phone: 3280012880
Fagron NV engages in the development, marketing, and distribution of healthcare products and services. The company is headquartered in Nazareth, Oost-Vlaanderen and currently employs 3,989 full-time employees. The company went IPO on 2007-10-05. The firm specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The company operates through the following segments: Essentials, enable pharmacists to compound safe products and optimize their compounding process with equipment and packaging. The portfolio includes pharmaceutical raw materials, compounding equipment, packaging, and supplies; Brands, focuses on developing semi-finished products and pharmaceutical-grade vehicles and reduce the workload for pharmacists; Compounding Services, utilizes raw materials from the Essentials segment and vehicles from the Brands segment for compounding activities, offering both sterile and non-sterile compounded products tailored to patients' specific needs.
The current stock price of FAGR.BR is 20.3 EUR. The price decreased by -0.49% in the last trading session.
FAGRON (FAGR.BR) has a dividend yield of 1.18%. The yearly dividend amount is currently 0.29.
FAGR.BR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
FAGRON (FAGR.BR) operates in the Health Care sector and the Health Care Providers & Services industry.
FAGRON (FAGR.BR) has a market capitalization of 1.50B EUR. This makes FAGR.BR a Small Cap stock.
ChartMill assigns a technical rating of 2 / 10 to FAGR.BR. When comparing the yearly performance of all stocks, FAGR.BR turns out to be only a medium performer in the overall market: it outperformed 55.22% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to FAGR.BR. While FAGR.BR belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months FAGR.BR reported a non-GAAP Earnings per Share(EPS) of 1.17. The EPS increased by 10% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.36% | ||
| ROA | 7.69% | ||
| ROE | 17.17% | ||
| Debt/Equity | 0.78 |
13 analysts have analysed FAGR.BR and the average price target is 25.65 EUR. This implies a price increase of 26.33% is expected in the next year compared to the current price of 20.3.
For the next year, analysts expect an EPS growth of 11.43% and a revenue growth 9.19% for FAGR.BR